Skip to main content
. 2019 Oct 18;10(3):488–497. doi: 10.1016/j.apsb.2019.10.004

Figure 5.

Figure 5

CHMFL-VEGFR2-002 inhibited tumor growth. (A) Anti-tumor efficacy of CHMFL-VEGFR2-002 in the peritoneal dissemination model. MKN45 cells were inoculated into nude mice and treated with DMSO, CHMFL-VEGFR2-002, and sunitinib. After 17 days, tumors in CHMFL-VEGFR2-002 group were significantly less than DMSO group (tumors are marked with arrows), *P < 0.05 versus control treatment. (B) Body weight monitoring of CHMFL-VEGFR2-002 in mouse xenograft model. (C) CHMFL-VEGFR2-002 increased the survival rate of C57 mice bearing B16-F10 compared with DMSO. Data are mean±SD (n=5).